We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting
A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations Progression Free
View HTML
Toggle Summary TESARO, Breast International Group (BIG), and the European Organization for Research and Treatment of Cancer (EORTC) Announce Collaboration for Niraparib Clinical Development in Breast Cancer
CHICAGO and BRUSSELS, Belgium, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, Breast International Group (BIG), a non-profit organization for academic breast cancer research groups from around the world, and the European Organization for
View HTML
Toggle Summary TESARO and the European Network of Gynecological Oncological Trial Groups (ENGOT) Forge Partnership to Develop Niraparib for Ovarian Cancer
CHICAGO, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and the European Network of Gynecological Oncological Trial Groups (ENGOT), a network of national and regional clinical trial organizations, today announced a partnership for the
View HTML
Toggle Summary TESARO to Webcast Investor Briefing at ASCO
WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) invites investors and the general public to listen to a webcast of a presentation by the TESARO management team at an investor briefing on Sunday, June 2, 2013 at 6:15 p.m. Central time, in connection with the annual
View HTML
Toggle Summary TESARO to Present at the Deutsche Bank 38th Annual 2013 Health Care Conference
WALTHAM, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President, will present at the Deutsche Bank 38 th Annual 2013 Health Care Conference at the Westin Boston Waterfront Hotel on
View HTML
Toggle Summary TESARO Announces Presentation of Niraparib Clinical Data at the 2013 ASCO Annual Meeting
Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer Phase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-Year Phase 3 Trial in Patients With Breast Cancer on Track to Initiate in 2H13 WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO Announces Election of Dr. James Armitage to Board of Directors and Results of Annual Stockholder Meeting
WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that James O. Armitage, M.D., F.A.C.P., F.R.C.P., has been elected to the TESARO Board of Directors. This election increases the number of independent directors
View HTML
Toggle Summary Tesaro Announces First-Quarter 2013 Operating Results
Phase 3 Trial of Niraparib in Breast Cancer to be Initiated in the Second Half of 2013 Phase 3 Trial of Niraparib in Ovarian Cancer on Track to Begin Enrolling Mid-2013 Top-Line Results of Rolapitant Phase 3 Program to be Announced in the Second Half of 2013 Fifth Dose Level Achieved in Phase 1/2
View HTML
Toggle Summary TESARO to Announce First Quarter 2013 Financial Results on April 25, 2013
WALTHAM, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2013 financial results on Thursday, April 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday,
View HTML
Toggle Summary TESARO to Present at the 20th Annual Future Leaders in the Biotech Industry Conference
WALTHAM, Mass., March 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 20 th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel and Conference
View HTML